Mechanistically, PRMT5 is thought to promote GBM malignancy by modulating signaling pathways including ERK1/2, PTEN/AKT/P27, and through its downstream effector suppressor of tumorigenicity 7 (ST7) [190–192]. This evidence concerns the gene CDKN1B and glioblastoma.